Insurance coverage, usual source of care, and receipt of clinically indicated care for comorbid conditions among adults living with human immunodeficiency virus

Medical Care

Volumn 43, Issue 4, 2005, Pages 401-410

  Goldstein, Risë B ^a,f   Rotheram Borus, Mary Jane ^a   Johnson, Mallory O ^b   Weinhardt, Lance S ^c   Remien, Robert H ^d   Lightfoot, Marguerita ^a   Catz, Sheryl L ^e   Gore Felton, Cheryl ^c   Kirshenbaum, Sheri ^d   Morin, Stephen F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

^f NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Addiction treatment; Antidepressants; Antiretroviral therapy; Comorbidity; HIV; Pneumocystis carinii pneumonia prophylaxis

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DAPSONE; FLUOXETINE; PENTAMIDINE; SERTRALINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DEPRESSION; DRUG USE; FEMALE; HEALTH CARE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL HEALTH; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; SUBSTANCE ABUSE; TREATMENT INDICATION; UNITED STATES;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMBULATORY CARE FACILITIES; ANTI-RETROVIRAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIDEPRESSIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEPRESSION; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HEALTH SERVICES; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; MEDICAID; PNEUMONIA, PNEUMOCYSTIS; PRIVATE PRACTICE; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 20244371039     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000156850.86917.f8     Document Type: Article

References (56)

1. Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Costs and Services Utilization. J AIDS. 2000;25:115-123.
2. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
3. Smith SR, Kirking DM. The effect of insurance coverage changes on drug utilization in HIV disease. J AIDS. 2001;28:140-149.
4. Keruly JC, Conviser R, Moore RD. Association of medical insurance and other factors with receipt of antiretroviral therapy. Am J Public Health. 2002;92:852-857.
5. Hsu LC, Vittinghoff E, Katz MH, et al. Predictors of use of highly active antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-1999. J AIDS. 2001;28:345-350.
6. Gardner LI, Holmberg SD, Moore J, et al. Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care. J AIDS. 2002;29:69-75.
7. Stall R, Pollack L, Mills TC, et al. Use of antiretroviral therapies among HIV-infected men who have sex with men: a household-based sample of 4 major American cities. Am J Public Health. 2001;91:767-773.
8. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15:1707-1715.
9. Knowlton AR, Hoover DR, Chung S, et al. Access to medical care and service utilization among injection drug users with HIV/AIDS. Drug Alcohol Depend. 2001;64:55-62.
10. Cronquist A, Edwards V, Galea S, et al. Health care utilization among young adult injection drug users in Harlem, New York. J Subst Abuse. 2001;13:17-27.
11. Druss BG, Hoff RA, Rosenheck RA. Underuse of antidepressants in major depression: prevalence and correlates in a national sample of young adults. J Clin Psychiatry. 2000;61:234-237.
12. Goldman LS, Nielsen NH, Champion HC, for the Council on Scientific Affairs, American Medical Association. Awareness, diagnosis, and treatment of depression. J Gen Intern Med. 1999;14:569-580.
13. Kosanke N, Magura S, Staines G, et al. Feasibility of matching alcohol patients to ASAM levels of care. Am J Addict. 2002;11:124-34.
14. Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA. 2002;287:203-209.
15. Sclar DA, Robison LM, Skaer TL, et al. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters. Int J Psychiatry Med. 1998;28:407-419.
16. Sturm R, Sherboume CD. Are barriers to mental health and substance abuse care still rising? J Behav Health Serv Res. 2001;28:81-88.
17. Wenzel SL, Burnam MA, Koegel P, et al. Access to inpatient or residential substance abuse treatment among homeless adults with alcohol or other drug use disorders. Med Care. 2001;39:1158-1169.
18. Wells KB, Sherbourne CD, Sturm R, et al. Alcohol, drug abuse, and mental health care for uninsured and insured adults. Health Serv Res. 2002;37:1055-1066.
19. Murray CJL, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science. 1996;274:740-743.
20. Sambamoorthi U, Moynihan PJ, McSpiritt E, et al. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS. Am J Public Health. 2001;91:1474-1481.
21. Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001;16:625-633.
22. Sambamoorthi U, Warner LA, Crystal S, et al. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug Alcohol Depend. 2000a;60:77-89.
23. Sambamoorthi U, Walkup J, Olfson M, et al. Antidepressant treatment and health services utilization among HIV-infected Medicaid patients diagnosed with depression. J Gen Intern Med. 2000b;15:311-320.
24. Fairfield KM, Libman H, Davis RB, et al. Brief communication: detecting depression: providing high quality primary care for HIV-infeccted patients. Am J Med Qual. 2001;16:71-74.
25. Starace F, Ammassari A, Trotta MP, et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S136-S139.
26. Alliance for Health Reform. Update on the Uninsured, January, 2002. Washington, DC: Author; 2002.
27. Johri M, Paltiel AD, Goldie SJ, et al. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care. 2002;40:429-441.
28. Hecht FM, Wilson IB, Wu AW, et al. Optimizing care for persons with HIV infection. Ann Intern Med. 1999;131:136-143.
29. Centers for Disease Control and Prevention. HIV/AIDS surveillance report: Midyear 2001 edition. MMWR. 2001;13:1.
30. Justice AC, Holmes W, Gifford AL, et al, for the Adult AIDS Clinical Trials Unit Outcomes Committee. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(Suppl 1):S77-S90.
31. Weatherby NL, Needles R, Cesari H, et al. Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Evaluation Program Planning. 1994;17:347-355.
32. Beck AT. Depression: Causes and Treatment. Philadelphia, PA: University of Pennsylvania Press; 1967.
33. Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol. 1984;40:1365-1367.
34. Shaver PR, Brennan KA. Measures of depression and loneliness. In Robinson JP, Shaver R, et al., eds. Measures of Personality and Social Psychological Attitudes. San Diego, CA: Academic Press, Inc; 1991: 195-289.
35. Lubeck DP, Fries JF. Changes in health status after one year for persons at-risk for and with HIV infection. Psychol Health. 1992;9:79-92.
36. Department of Health and Human Services and Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. May, 2002, update. Available at http://www.aidsinfo.nih.gov/ guidelines/archive.asp. Accessed January 20, 2005.
37. Department of Health and Human Services and Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. January, 2000, update. Available at http://www.aidsinfo.nih.gov/ guidelines/archive.asp. Accessed January 20, 2005.
38. Department of Health and Human Services and Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February, 2001, update. Available at http://www.aidsinfo.nih.gov/ guidelines/archive.asp. Accessed January 20, 2005.
39. Department of Health and Human Services and Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. August, 2001, update. Available at http://www.aidsinfo.nih.gov/ guidelines/archive.asp. Accessed January 20, 2005.
40. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons-2002 recommendations of the U.S. Public Health Service and the Infectious Disease Society of America. MMWR. 2002;RR-8:51.
41. Turner CF, Ku L, Rogers SM, et al. Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science. 1998;280:867-873.
42. Gribble JN, Miller HG, Rogers SM, et al. Interview mode and measurement of sexual behaviors: methodological issues. J Sex Res. 1999;36:16-24.
43. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: John Wiley & Sons; 2000.
44. SAS Institute, Inc. SAS Statistical Software, Version 8. Cary, NC: SAS Institute, Inc; 1999.
45. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
46. Shi L. The convergence of vulnerable characteristics and health insurance in the U.S. Soc Sci Med. 2001;53:519-529.
47. Smith SR, Buchanan RJ. The AIDS Drug Assistance Programs and coverage of HIV-related medications. Ann Pharmacother. 2001;35:155-166.
48. Santerre RE. The inequity of Medicaid reimbursement in the United States. Appl Health Econ Health Policy. 2002;1:25-32.
49. Trude S. Patient cost sharing: how much is too much? Issue Brief Cent Stud Health Syst Change. 2003;72:1-4.
50. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
51. Kalichman SC, Rompa D, Cage M. Reliability and validity of self-reported CD4 lymphocyte count and viral load test results in people living with HIV/AIDS. Int J STD AIDS. 2000;11:579-585.
52. Weissman JS, Levin K, Chasan-Taber S, et al. The validity of self-reported health-care utilization by AIDS patients. AIDS. 1996;10:775-783.
53. Kiberd BA, Clase CM. Cumulative risk for developing end-stage renal disease in the U.S. population. J Am Soc Nephrol. 2002;13:1635-1644.
54. Asch SM, Gifford AL, Bozzette SA, et al. Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States. J AIDS. 2001;28:340-344.
55. Hirschfeld RMA, Keller MB, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277:333-340.
56. Green-Hennessy S. Factors associated with receipt of behavioral health services among persons with substance dependence. Psychiatric Services. 2002;53:1592-1598.